Offenbach takes off: BioSpring is building a high-tech plant for pharmaceuticals!

Offenbach takes off: BioSpring is building a high-tech plant for pharmaceuticals!

The groundbreaking ceremony for the new plant of the biotechnology company BioSpring in Offenbach took place on July 3, 2025. At this ceremony, Prime Minister Boris Rhein emphasized the strength of Hesse as a biotechnology location. BioSpring, considered a “model company,” will build one of the world's largest production facilities for pharmaceutical active ingredients based on RNA and DNA.

Research at the new facility pursues the ambitious goal of finding cures for diseases such as Alzheimer's and cancer. With this expansion, BioSpring underlines its leading role in the global market for the production and analysis of synthetic nucleic acids. The company plans to invest hundreds of millions at its new location in Offenbach by 2027.

Economic importance and jobs

The new building will also create 200 new jobs in the region. Rhein highlighted the strategic importance of these investments, particularly for technological competence and high-tech pharmaceutical production in Germany. In view of international dependencies, he emphasized the importance of ensuring security of supply and value creation in the country.

BioSpring will be located on just under one hectare on Kettelerstrasse in the Offenbach innovation campus. The innovation campus, which covers a total area of ​​36 hectares, offers 26 hectares for commercial development. The company plans to convert former Farbwerke Hoechst social buildings, with the demolition of the former canteen building and the construction of a modern production hall being planned.

Leading role in biotechnology

BioSpring, which was founded in 1997 and is owner-managed, currently employs over 370 people and was recognized as Hessen Champion in the job engine category. It is a leader in the production of synthetic DNA fragments for therapeutic applications used in therapy, diagnostics and research. This also includes oligonucleotides, which are the main component of PCR tests, including for COVID-19.

The city of Offenbach is working in parallel on a development plan and the development of the commercial area in order to promote the settlement of new companies. Mayor Dr. Felix Schwenke welcomes the initiative and sees the collaboration with Samson AG, which was the first provider to expand in the innovation campus in 2021, as a success factor for BioSpring's establishment.

Overall, BioSpring's commitment indicates a promising development for the biotechnology industry in Hesse, both in terms of innovation and the creation of high-quality jobs.

For more information, see the report from hessen.de as well as on bionity.com.